Celiac Disease Market to Reach $2,679.28 Million by 2035
Celiac disease market is driven by the increasing prevalence of autoimmune and gastrointestinal disorders, growing awareness regarding gluten intolerance, and rising demand for advanced diagnostic and treatment solutions. The adoption of serologic tests, genetic testing, and small-bowel biopsy procedures is increasing for accurate diagnosis and early disease detection. Additionally, growing demand for gluten-free dietary supplements, advancements in therapeutic vaccines, increasing healthcare expenditure, and expanding research activities focused on autoimmune disease management are further supporting the growth of the global celiac disease market.
Browse the full report description of “Celiac Disease Market Size, Share & Trends Analysis Report by Treatment Type (Vitamins and Dietary (Gluten-Free) Supplements, Steroids and Immunosuppressive Drugs, and Therapeutic Vaccines), By Diagnostic Type (Serologic Test, Genetic Testing, and Small-Bowel Biopsy) By End-User (Hospitals and Diagnostics Centers, and Research Institutes), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/celiac-disease-market/
Anokion KAN-101 clinical development is expected to support advanced celiac disease treatment innovation in 2025
Anokion continued the clinical development of KAN-101 during 2024–2025, targeting immune tolerance induction for patients with celiac disease. The development is expected to support growing innovation in targeted immunotherapy solutions for autoimmune gastrointestinal disorders. Increasing prevalence of celiac disease, rising awareness regarding autoimmune digestive conditions, and growing demand for alternatives to strict gluten-free diets are key factors driving research and development activities in the celiac disease treatment market. KAN-101’s focus on antigen-specific immune tolerance induction is expected to support the advancement of precision immunotherapy approaches aimed at improving long-term disease management and patient outcomes.
Barinthus Biotherapeutics celiac disease immunotherapy development is expected to strengthen antigen-specific treatment approaches in 2025
Barinthus Biotherapeutics advanced clinical development activities for its celiac disease immunotherapeutic candidate during 2024–2025 with a focus on antigen-specific immune tolerance approaches. The development is expected to contribute to the growing adoption of next-generation immunotherapies for autoimmune diseases and chronic gastrointestinal disorders. Increasing investment in biotechnology research, rising demand for targeted therapeutic solutions, and ongoing advancements in immune modulation technologies are driving innovation in the celiac disease therapeutics market. The company’s antigen-specific immunotherapy program is expected to support the development of more personalized and effective treatment options for patients with celiac disease while reducing dependence on dietary management alone.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404